A Vision for Drug Discovery and Development: Novel Targets and Multilateral Partnerships
Open accessThe DOI matches its Crossref record.
Abstract
Dear Colleague, Paradigm strain exists in psychiatric pharmacology. The prevailing monoamine-based psychotropic agents have in some circumstances saved lives, robustly benefitted patient reported outcomes (e.g., quality of life measures, functionality), and have facilitated reintegration and recovery. Unfortunately, these foregoing desirable outcomes are an uncommon occurrence for most individuals who receive existing treatments. For the common and severe brain disorders (e.g., mood, anxiety, and psychotic disorders), the insufficiency of extant treatments has provided the impetus to evaluate the role of other targets/systems. Moreover, there is consensus that available psychotropic agents are not “disease-modifing” and are rather symptom suppressing an/or providing only for temporary adaptation. The paradigm strain of the monoamine hypotheses has resulted in a large number of antidepressants and antipsychotics that are not genuinely novel when compared to some of the erstwhile psychotropics (e.g., tricyclic antidepressants). It is however, incorrect to conclude that all antidepressants and antipsychotics are identical (they clearly are not), as evidenced by their tolerability, efficacy, and pharmacological profile. The business model in CNS therapeutics has fostered a level of complacency in drug discovery wherein, until recently, the return on investment has justified a maintenance of status quo. The genericization of most psychotropic medicine, the “patent cliff” experienced by many blockbuster psychiatric medicines, and the lack of reimbursement by public/private payers has contributed to a lack of enthusiasm for drug development for psychiatric disorders. This foregoing confluence of factors could, however, provide the impetus for a different approach to drug discovery and development. Going forward, psychiatry, and its granting agencies, could do a much better job at instantiating viable clinical targets for psychiatric syndromes. Moreover, multilateral partnerships in other therapeutic areas (e.g., HIV-AIDS) have resulted in not only genuinely novel and revolutionary treatments, but treatments that are delivered in short time to the principal stakeholder, i.e., the patient. During the next 1–2 years, psychiatry will continue to identify agents that are refinement and evolution of existing agents. In some cases, these agents may represent structural optimization from an existing progenitor molecule already in the clinical ecosystem. Contemporaneous with these foregoing developments are identification of agents with novel targets (e.g., intranasal ketamine, agents that target cellular bioenergetics/inflammation). Moreover exploring the pluripotentiality of stem cells seems an exciting opportunity. Targeting many of the foregoing molecular systems is conveniently possible by repurposing some of the over 20,000 medicinal agents that are available globally. Examples of this have been observed in other therapeutic areas (e.g., the use of agents primarily intended for oncology to treat macular degeneration). Where does that leave us? During the next 1–2 years, we will see new agents that have unique effects on monoaminergic systems (e.g., vortioxetine, levomilnacipran). The pursuit of mechanistically novel agents will be fuelled by scientific, clinical, economic, and health systems factors. It certainly has been identified that a yawning chasm exists between developments in neuroscience and genuinely novel “neuro-glial” pharmacology. It is unlikely that in 1–2 years the gap will witness a significant narrowing; it is, however, not unreasonable to expect the next 1–2 years to provide an empirical edifice for public, private, advocacy, and non-governmental organization support for unique psychotropic agents that are capable of modifying disease course. I have found the developments in HIV-AIDS treatment to be the closest metaphor and inspiration for psychiatric therapeutics. On June 5, 1981, the first case of HIV-AIDS was identified in South Central Los Angeles. A year ago, the Centers for Disease Control and Prevention declared HIV-AIDS a chronic disease. This highly stigmatized condition which was a death sentence during the 1980s and 1990s, has witnessed such remarkable change in large part due to the openness to explore viable targets supported by multilateral partnership with an expectation of treatment availability in the very near future rather than some nebulous future date. Psychiatry has not historically embraced multilateral partnerships—at its peril. The future, however, can look very bright if psychiatry embraces a multilateral pursuit of novel targets, provides bold leadership intellectually, and there is sufficient reward for sponsors who take the risk of investing in such pursuits. Roger S. McIntyre
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bipolar Disorder and Inflammation
Rosenblat, J. D., & McIntyre, R. S. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.09.006 · Cited by 186
Self-citationMcIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145
Self-citationThe Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis
McIntyre, R. S., Lee, Y., Zhou, A. J., Rosenblat, J. D., Peters, E. M., Lam, R. W., Kennedy, S. H., Rong, C., & Jerrell, J. M. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000723 · Cited by 75
Self-citationKorkmaz, Ş. A., & Kızgın, S. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2260302 · Cited by 33
Christensen, M. C., Florea, I., Loft, H., & McIntyre, R. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.074 · Cited by 26
Self-citation
Metadata
- Authors
- McIntyre, R. S.
- Venue
- Advances in Therapy
- Published
- 2014-03
- Volume
- 31
- Issue
- 3
- Pages
- 245-246
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W2030454755
- Cited by
- 23
- References
- 0
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Vision for Drug Discovery and Development: Novel Targets and Multilateral Partnerships. https://app.cochat.ai/papers/10.1007/s12325-014-0105-0
- The paper
- McIntyre, R. S. (2014). A Vision for Drug Discovery and Development: Novel Targets and Multilateral Partnerships. Advances in Therapy. https://doi.org/10.1007/s12325-014-0105-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.